Xia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xia Wang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Anwen Liu
The Second Affiliated Hospital of Nanchang University 1 Department of Oncology Nanchang, PR China
7 shared publications - Kefeng Wang
Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China
6 shared publications - Peng Jin
Senior Department of Gastroenterology, Chinese PLA General Hospital, Beijing, China
6 shared publications - Wei Jin
Department of Heart Center, Tianjin Third Central Hospital, Tianjin, China
6 shared publications - Xiang Fei
Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, People’s Republic of China
6 shared publications - Xiaonan Chen
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
6 shared publications
Latest Publications
- Open Access
- 30 June 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Prognostic Role of Radiotherapy in Low-Grade Endometrial Stromal Sarcoma: A SEER-Based Study
Introduction: Low-grade endometrial stromal sarcoma (LG-ESS) is a rare malignant mesenchymal neoplasm for which there is no consensus regarding the role of radiotherapy in treatment. This study aimed to evaluate the prognostic significance of external beam radiotherapy (EBRT) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: This retrospective study evaluated the role of EBRT in 1254 patients with LG-ESS using SEER data (2000-2021). Propensity score matching (PSM) was applied to compare outcomes between EBRT and non-EBRT groups. Cox and competing risk models assessed overall survival (OS) and cancer-specific survival (CSS). Results: EBRT showed no survival benefit in either unmatched or matched cohorts. Post-PSM, OS (HR = 1.21, 95% CI 0.61-2.39) and CSS (HR = 1.75, 95% CI 0.69-4.43) remained unaffected by EBRT ( P > 0.05). Lymphadenectomy and bilateral salpingectomy and oophorectomy (BSO) also demonstrated no significant associations with survival outcomes. Key prognostic factors included older age, larger tumor size, advanced stage, and chemotherapy use, all linked to poorer OS and CSS. Conclusion: EBRT, lymphadenectomy, and BSO do not offer significant survival benefits for patients with LG-ESS. Prognosis was independently influenced by age, tumor size, stage, and chemotherapy use (associated with poorer outcomes). These findings support a more individualized, risk-adapted approach to LG-ESS management and highlight the need for prospective studies to define the optimal role of comprehensive treatment strategies.
- 30 June 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Open AccessPrognostic Role of Radiotherapy in Low-Grade Endometrial Stromal Sarcoma: A SEER-Based Study
Introduction: Low-grade endometrial stromal sarcoma (LG-ESS) is a rare malignant mesenchymal neoplasm for which there is no consensus regarding the role of radiotherapy in treatment. This study aimed to evaluate the prognostic significance of external beam radiotherapy (EBRT) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: This retrospective study evaluated the role of EBRT in 1254 patients with LG-ESS using SEER data (2000-2021). Propensity score matching (PSM) was applied to compare outcomes between EBRT and non-EBRT groups. Cox and competing risk models assessed overall survival (OS) and cancer-specific survival (CSS). Results: EBRT showed no survival benefit in either unmatched or matched cohorts. Post-PSM, OS (HR = 1.21, 95% CI 0.61-2.39) and CSS (HR = 1.75, 95% CI 0.69-4.43) remained unaffected by EBRT ( P > 0.05). Lymphadenectomy and bilateral salpingectomy and oophorectomy (BSO) also demonstrated no significant associations with survival outcomes. Key prognostic factors included older age, larger tumor size, advanced stage, and chemotherapy use, all linked to poorer OS and CSS. Conclusion: EBRT, lymphadenectomy, and BSO do not offer significant survival benefits for patients with LG-ESS. Prognosis was independently influenced by age, tumor size, stage, and chemotherapy use (associated with poorer outcomes). These findings support a more individualized, risk-adapted approach to LG-ESS management and highlight the need for prospective studies to define the optimal role of comprehensive treatment strategies.
- Open Access
- 1 January 2025
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2025 (1) , 9983293
Divergent Survival Outcomes With Adjuvant Chemotherapy in Stage IA Ovarian Clear Cell Carcinoma: Insights From the SEER Database
Background: This study aims to evaluate the impact of adjuvant chemotherapy on cancer‐specific survival (CSS) and overall survival (OS) in patients with Stage IA ovarian clear cell carcinoma (OCCC) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We conducted a retrospective cohort study utilizing SEER data (2000–2021) to compare the prognosis of Stage IA OCCC patients who received adjuvant chemotherapy versus those who did not. Propensity score matching (PSM) was used to balance baseline characteristics between the groups. Competing risks regression and multivariate Cox regression analyses identified prognostic factors for CSS and OS. Results: A total of 1422 Stage IA OCCC patients were identified. After PSM, 776 patients (388 in each group) were included. For patients aged ≤ 50 years, chemotherapy was linked to worse CSS (89.5% vs. 96.2%, p = 0.007) and OS (89.3% vs. 95.9%, p = 0.008). Conversely, in patients aged > 70 years, chemotherapy was associated with improved CSS (93.0% vs. 81.9%, p = 0.038) and OS (86.0% vs. 72.4%, p = 0.006). These trends remained after PSM. Multivariate analysis showed that chemotherapy had little impact on OS and CSS. Subgroup analysis further indicated that chemotherapy negatively affected CSS and OS in patients aged ≤ 50 years. Conclusions: Adjuvant chemotherapy did not significantly improve survival outcomes in patients with Stage IA OCCC. However, its effects were age‐dependent, with older patients (> 70 years) experiencing improved survival, while younger patients (≤ 50 years) exhibited worse outcomes. These findings underscore the importance of individualized treatment strategies for Stage IA OCCC.
- 1 January 2025
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2025 (1) , 9983293
Open AccessDivergent Survival Outcomes With Adjuvant Chemotherapy in Stage IA Ovarian Clear Cell Carcinoma: Insights From the SEER Database
Background: This study aims to evaluate the impact of adjuvant chemotherapy on cancer‐specific survival (CSS) and overall survival (OS) in patients with Stage IA ovarian clear cell carcinoma (OCCC) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We conducted a retrospective cohort study utilizing SEER data (2000–2021) to compare the prognosis of Stage IA OCCC patients who received adjuvant chemotherapy versus those who did not. Propensity score matching (PSM) was used to balance baseline characteristics between the groups. Competing risks regression and multivariate Cox regression analyses identified prognostic factors for CSS and OS. Results: A total of 1422 Stage IA OCCC patients were identified. After PSM, 776 patients (388 in each group) were included. For patients aged ≤ 50 years, chemotherapy was linked to worse CSS (89.5% vs. 96.2%, p = 0.007) and OS (89.3% vs. 95.9%, p = 0.008). Conversely, in patients aged > 70 years, chemotherapy was associated with improved CSS (93.0% vs. 81.9%, p = 0.038) and OS (86.0% vs. 72.4%, p = 0.006). These trends remained after PSM. Multivariate analysis showed that chemotherapy had little impact on OS and CSS. Subgroup analysis further indicated that chemotherapy negatively affected CSS and OS in patients aged ≤ 50 years. Conclusions: Adjuvant chemotherapy did not significantly improve survival outcomes in patients with Stage IA OCCC. However, its effects were age‐dependent, with older patients (> 70 years) experiencing improved survival, while younger patients (≤ 50 years) exhibited worse outcomes. These findings underscore the importance of individualized treatment strategies for Stage IA OCCC.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from miR-211-5p Suppresses Metastatic Behavior by Targeting SNAI1 in Renal Cancer
The Snail family transcriptional repressor 1 (SNAI1) is known to promote metastatic phenotypes in renal cell carcinoma (RCC). However, the mechanism by which SNAI1 promotes RCC metastasis remains largely unexplored. Here, bioinformatics and quantitative validation revealed that miR-211-5p was downregulated in metastatic RCC clinical specimens compared with nonmetastatic RCC tissues. Overexpression of miR-211-5p suppressed RCC cell migration and invasion via downregulation of SNAI1 expression. Luciferase reporter assays demonstrated that miR-211-5p directly targeted 3′-UTR of SNAI1. Furthermore, miR-211-5p decreased xenograft tumor weight and reduced in vivo tumor metastasis in mice. These findings indicate that miR-211-5p-mediated inhibition of SNAIL1 expression contributes to the suppression of RCC progression.Implications: Targeting the miR-211-5p/SNAI1 signaling pathway may be a novel therapeutic approach for the treatment of RCC metastasis. Mol Cancer Res; 15(4); 448–56. ©2017 AACR.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from miR-211-5p Suppresses Metastatic Behavior by Targeting SNAI1 in Renal Cancer
The Snail family transcriptional repressor 1 (SNAI1) is known to promote metastatic phenotypes in renal cell carcinoma (RCC). However, the mechanism by which SNAI1 promotes RCC metastasis remains largely unexplored. Here, bioinformatics and quantitative validation revealed that miR-211-5p was downregulated in metastatic RCC clinical specimens compared with nonmetastatic RCC tissues. Overexpression of miR-211-5p suppressed RCC cell migration and invasion via downregulation of SNAI1 expression. Luciferase reporter assays demonstrated that miR-211-5p directly targeted 3′-UTR of SNAI1. Furthermore, miR-211-5p decreased xenograft tumor weight and reduced in vivo tumor metastasis in mice. These findings indicate that miR-211-5p-mediated inhibition of SNAIL1 expression contributes to the suppression of RCC progression.Implications: Targeting the miR-211-5p/SNAI1 signaling pathway may be a novel therapeutic approach for the treatment of RCC metastasis. Mol Cancer Res; 15(4); 448–56. ©2017 AACR.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from miR-211-5p Suppresses Metastatic Behavior by Targeting SNAI1 in Renal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from miR-211-5p Suppresses Metastatic Behavior by Targeting SNAI1 in Renal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from miR-211-5p Suppresses Metastatic Behavior by Targeting SNAI1 in Renal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from miR-211-5p Suppresses Metastatic Behavior by Targeting SNAI1 in Renal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from miR-211-5p Suppresses Metastatic Behavior by Targeting SNAI1 in Renal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from miR-211-5p Suppresses Metastatic Behavior by Targeting SNAI1 in Renal Cancer
- Open Access
- 5 August 2022
- Published by Chinese Chemical Society in CCS Chemistry
- Vol. 4 (8) , 2581-2587
Molecularly Engineered Aptamers Targeting Tumor Tissue and Cancer Cells for Efficient in Vivo Recognition and Enrichment
Molecular engineering of aptamers can confer exogenous biomedical properties that may be beneficial for various biomedical applications. In this study, a tumor-homing peptide modification strategy ... Description
- 5 August 2022
- Published by Chinese Chemical Society in CCS Chemistry
- Vol. 4 (8) , 2581-2587
Open AccessMolecularly Engineered Aptamers Targeting Tumor Tissue and Cancer Cells for Efficient in Vivo Recognition and Enrichment
Molecular engineering of aptamers can confer exogenous biomedical properties that may be beneficial for various biomedical applications. In this study, a tumor-homing peptide modification strategy ... Description
- Open Access
- 1 June 2022
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 15, 651-657
FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
Background: Fibroblast growth factor receptor (FGFR) fusions in non-small cell lung cancer (NSCLC) are small genomic events. At present, there is no standard treatment strategy for patients with NSCLC carrying an FGFR fusion. Case Presentation: We report the case of a 45-year-old female patient who was diagnosed with lung adenocarcinoma and underwent right upper lobectomy and postoperative adjuvant chemotherapy. After 13 months, the patient’s lung lesions progressed. Next-generation sequencing of venous blood and lung tissues confirmed an FGFR2-ERC1 fusion, and she received chemotherapy and immunotherapy. Two months later, the patient’s lung lesions progressed again. Based on the target effect of anlotinib on FGFR, the patient was subsequently treated with anlotinib, and the progression-free survival interval exceeded 8.0 months. Conclusion: These findings showed that patients with lung adenocarcinoma carrying an FGFR2-ERC1 fusion gene may benefit from anlotinib. This case provided evidence to support the use of anlotinib in the treatment of NSCLC patients with FGFR fusion gene subtypes.
- 1 June 2022
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 15, 651-657
Open AccessFGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
Background: Fibroblast growth factor receptor (FGFR) fusions in non-small cell lung cancer (NSCLC) are small genomic events. At present, there is no standard treatment strategy for patients with NSCLC carrying an FGFR fusion. Case Presentation: We report the case of a 45-year-old female patient who was diagnosed with lung adenocarcinoma and underwent right upper lobectomy and postoperative adjuvant chemotherapy. After 13 months, the patient’s lung lesions progressed. Next-generation sequencing of venous blood and lung tissues confirmed an FGFR2-ERC1 fusion, and she received chemotherapy and immunotherapy. Two months later, the patient’s lung lesions progressed again. Based on the target effect of anlotinib on FGFR, the patient was subsequently treated with anlotinib, and the progression-free survival interval exceeded 8.0 months. Conclusion: These findings showed that patients with lung adenocarcinoma carrying an FGFR2-ERC1 fusion gene may benefit from anlotinib. This case provided evidence to support the use of anlotinib in the treatment of NSCLC patients with FGFR fusion gene subtypes.